InflaRx N.V. (IFRX) vs Sionna Therapeutics (SION)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
InflaRx N.V. (IFRX) has outperformed Sionna Therapeutics (SION) over the past year, gaining 4.1% versus a loss of 82.8%. InflaRx N.V. is the larger company by market cap ($225.5 million vs $221.2 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IFRX | SION |
|---|---|---|
| Share price | $1.53 | $4.90 |
| Market cap | $225.47M | $221.24M |
| 1-day change | -1.92% | +1.66% |
| YTD return | +51.49% | -88.09% |
| 1-year return | +4.08% | -82.81% |
| 5-year return | -38.06% | — |
| EPS (TTM) | $-0.58 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $2.95 | $54.97 |
| 52-week low | $0.798 | $4.01 |
| Distance from 52-week high | -48.12% | -91.09% |
| Analyst consensus | none | hold |
| Avg. price target upside | +400.65% | +328.57% |
| Average volume | 798.72K | 2.19M |
| Shares outstanding | 147.37M | 45.15M |
| Employees | 65 | 59 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IFRX has outperformed SION by 86.9 percentage points over the past year.
- The two companies sit in different sectors: InflaRx N.V. in Healthcare and Sionna Therapeutics in Health Care.
About InflaRx N.V.
IFRX stock →InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.
Healthcare · Biotechnology · 65 employees
About Sionna Therapeutics
SION stock →Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 59 employees
IFRX vs SION FAQ
Which is bigger, InflaRx N.V. or Sionna Therapeutics?
InflaRx N.V. (IFRX) is larger, with a market capitalization of $225.47M compared with $221.24M for Sionna Therapeutics (SION).
Which stock has performed better over the past year, IFRX or SION?
IFRX returned +4.08% over the past 12 months, compared with -82.81% for SION (price return, excluding dividends). Past performance does not predict future results.
Are InflaRx N.V. and Sionna Therapeutics in the same industry?
No. InflaRx N.V. is in the Healthcare sector, while Sionna Therapeutics is in Health Care.